Reporting of Patient-Reported Outcomes in Randomized Trials The CONSORT PRO Extension

被引:978
作者
Calvert, Melanie [1 ]
Blazeby, Jane [2 ]
Altman, Douglas G. [3 ]
Revicki, Dennis A. [4 ]
Moher, David [5 ]
Brundage, Michael D. [6 ]
机构
[1] Univ Birmingham, Sch Hlth & Populat Sci, Birmingham B15 2TT, W Midlands, England
[2] Univ Bristol, Sch Social & Community Med, Bristol BS8 1TH, Avon, England
[3] Univ Oxford, Ctr Stat Med, Oxford OX1 2JD, England
[4] United BioSource Corp, Outcomes Res, Bethesda, MD USA
[5] Ottawa Hosp, Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
[6] Queens Univ, Canc Res Inst, Kingston, ON, Canada
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2013年 / 309卷 / 08期
基金
英国医学研究理事会; 加拿大健康研究院;
关键词
QUALITY-OF-LIFE; LOW-BACK-PAIN; PHASE-III; EUROPEAN-ORGANIZATION; CLINICAL-TRIAL; MISSING DATA; CANCER; THERAPY; GEMCITABINE; PACLITAXEL;
D O I
10.1001/jama.2013.879
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The CONSORT (Consolidated Standards of Reporting Trials) Statement aims to improve the reporting of randomized controlled trials (RCTs); however, it lacks guidance on the reporting of patient-reported outcomes (PROs), which are often inadequately reported in trials, thus limiting the value of these data. In this article, we describe the development of the CONSORT PRO extension based on the methodological framework for guideline development proposed by the Enhancing the Quality and Transparency of Health Research (EQUATOR) Network. Five CONSORT PRO checklist items are recommended for RCTs in which PROs are primary or important secondary end points. These recommendations urge that the PROs be identified as a primary or secondary outcome in the abstract, that a description of the hypothesis of the PROs and relevant domains be provided (ie, if a multidimensional PRO tool has been used), that evidence of the PRO instrument's validity and reliability be provided or cited, that the statistical approaches for dealing with missing data be explicitly stated, and that PRO-specific limitations of study findings and generalizability of results to other populations and clinical practice be discussed. Examples and an updated CONSORT flow diagram with PRO items are provided. It is recommended that the CONSORT PRO guidance supplement the standard CONSORT guidelines for reporting RCTs with PROs as primary or secondary outcomes. Improved reporting of PRO data should facilitate robust interpretation of the results from RCTs and inform patient care. JAMA. 2013;309(8):814-822
引用
收藏
页码:814 / 822
页数:9
相关论文
共 37 条
[1]   Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and KRAS-Specific Results of the NCIC CTG and AGITG CO.17 Trial [J].
Au, Heather-Jane ;
Karapetis, Christos S. ;
O'Callaghan, Chris J. ;
Tu, Dongsheng ;
Moore, Malcolm J. ;
Zalcberg, John R. ;
Kennecke, Hagen ;
Shapiro, Jeremy D. ;
Koski, Sheryl ;
Pavlakis, Nick ;
Charpentier, Danielle ;
Wyld, David ;
Jefford, Michael ;
Knight, Gregory J. ;
Magoski, Nadine M. ;
Brundage, Michael D. ;
Jonker, Derek J. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1822-1828
[2]   The Missing Voice of Patients in Drug-Safety Reporting [J].
Basch, Ethan .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (10) :865-869
[3]   Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial [J].
Bischoff, Erik W. M. A. ;
Akkermans, Reinier ;
Bourbeau, Jean ;
van Weel, Chris ;
Vercoulen, Jan H. ;
Schermer, Tjard R. J. .
BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
[4]   Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European Organization for Research and Treatment of Cancer Breast Cancer Group, investigational drug branch for breast cancer and the new drug development group study [J].
Bottomley, A ;
Biganzoli, L ;
Cufer, T ;
Coleman, RE ;
Coens, C ;
Efficace, F ;
Calvert, HA ;
Gamucci, T ;
Twelves, C ;
Fargeot, P ;
Piccart, M .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2576-2586
[5]   Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma: A Phase III Randomized Controlled Trial of Health-Related Quality of Life and Symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group [J].
Bottomley, Andrew ;
Coens, Corneel ;
Suciu, Stefan ;
Santinami, Mario ;
Kruit, Willem ;
Testori, Alessandro ;
Marsden, Jeremy ;
Punt, Cornelis ;
Sales, Francois ;
Gore, Martin ;
MacKie, Rona ;
Kusic, Zvonko ;
Dummer, Reinhard ;
Patel, Poulam ;
Schadendorf, Dirk ;
Spatz, Alain ;
Keilholz, Ulrich ;
Eggermont, Alexander .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18) :2916-2923
[6]   Patient-reported outcomes in randomized clinical trials: development of ISOQOL reporting standards [J].
Brundage, Michael ;
Blazeby, Jane ;
Revicki, Dennis ;
Bass, Brenda ;
de Vet, Henrica ;
Duffy, Helen ;
Efficace, Fabio ;
King, Madeleine ;
Lam, Cindy L. K. ;
Moher, David ;
Scott, Jane ;
Sloan, Jeff ;
Snyder, Claire ;
Yount, Susan ;
Calvert, Melanie .
QUALITY OF LIFE RESEARCH, 2013, 22 (06) :1161-1175
[7]   Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers [J].
Brundage, Michael ;
Bass, Brenda ;
Davidson, Judith ;
Queenan, John ;
Bezjak, Andrea ;
Ringash, Jolie ;
Wilkinson, Anna ;
Feldman-Stewart, Deb .
QUALITY OF LIFE RESEARCH, 2011, 20 (05) :653-664
[8]   Facilitated physical activity as a treatment for depressed adults: randomised controlled trial [J].
Chalder, Melanie ;
Wiles, Nicola J. ;
Campbell, John ;
Hollinghurst, Sandra P. ;
Haase, Anne M. ;
Taylor, Adrian H. ;
Fox, Kenneth R. ;
Costelloe, Ceire ;
Searle, Aidan ;
Baxter, Helen ;
Winder, Rachel ;
Wright, Christine ;
Turner, Katrina M. ;
Calnan, Michael ;
Lawlor, Deborah A. ;
Peters, Tim J. ;
Sharp, Deborah J. ;
Montgomery, Alan A. ;
Lewis, Glyn .
BMJ-BRITISH MEDICAL JOURNAL, 2012, 344
[9]   SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials [J].
Chan, An-Wen ;
Tetzlaff, Jennifer M. ;
Altman, Douglas G. ;
Laupacis, Andreas ;
Gotzsche, Peter C. ;
Krleza-Jeric, Karmela ;
Hrobjartsson, Asbjorn ;
Mann, Howard ;
Dickersin, Kay ;
Berlin, Jesse A. ;
Dore, Caroline J. ;
Parulekar, Wendy R. ;
Summerskill, William S. M. ;
Groves, Trish ;
Schulz, Kenneth F. ;
Sox, Harold C. ;
Rockhold, Frank W. ;
Rennie, Drummond ;
Moher, David .
ANNALS OF INTERNAL MEDICINE, 2013, 158 (03) :200-+
[10]   Empirical evidence for selective reporting of outcomes in randomized trials -: Comparison of Protocols to published articles [J].
Chan, AW ;
Hróbjartsson, A ;
Haahr, MT ;
Gotzsche, PC ;
Altman, DG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (20) :2457-2465